Improving Lives Through
Innovative Diagnostic Solutions
AXIM is an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics solutions
Improving Lives Through
Innovative Diagnostic Solutions
AXIM is an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics solutions
COVID-19 TESTING
AXIM Biotech has developed a rapid (10-minute) serological diagnostic test that detects SARS-CoV-2 neutralizing antibodies (Nabs) which are the antibodies needed to fight COVID-19 within the body.
AXIM EYE
AXIM looks to assist doctors in diagnosing dry eye disease (DED) faster and more efficiently than alternative methods.
CANCER dIAGNOSTICS
AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer
The Latest On Our Research
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing the landscape of diagnosis of SARS-CoV-2 (COVID-19), dry eye disease (DED) and Oncological indications. AXIM’s COVID-19 neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and ophthalmological conditions such as DED.
AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has successfully developed a rapid...
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that is has shifted its focus for its rapid...
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab Testing Exec Barry Craig AXIM develops and files for a patent for...